Nasdaq-listed Capnia Inc. plans to acquire privately held Essentialis Inc. through a merger designed to create a combined developer of rare disease treatments,
Under the deal's terms announced Dec. 27, Capnia will issue common stock priced at $0.96 per share to a syndicate comprised of current and new investors, raising gross proceeds of...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?